Cell-free DNA can be used for non-invasive cancer detection and disease monitoring to enhance personalized medicine.

A cutting-edge diagnostic test is helping some doctors find diagnoses for medical mysteries by analyzing DNA and RNA to ...

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we ...

Researchers developed MethylGPT, a powerful transformer-based model that identifies DNA methylation patterns, enabling ...

technologies are allowing scientists to sequence DNA faster and expand knowledge of the genetic basis of disease. NGS is showing particular promise in areas where current diagnostic methods have ...

纽约 - PAVmed Inc. (NASDAQ:PAVM)的子公司Lucid Diagnostics Inc. (NASDAQ:LUCD)宣布扩大其直接合同计划，以增加其EsoGuard食管DNA检测的收入。这项扩展包括全面合同的癌前检测活动、特需医疗和雇主市场。Lucid最近从GRAIL, Inc.聘请了两位行业专家来支持这些努力。

The company describes the precision medicine test as the first of its kind to offer simultaneous whole exome sequencing and ...

LMU chemists have developed a versatile biosensor using DNA origami that can easily adapt to various biomolecular targets.

Pancreatic cancer (PC) presents substantial diagnostic challenges due to its aggressive nature and lack of early symptoms, ...

Photosensitive metal complexes that are able to bind to DNA duplexes hold promise for diagnostic and therapeutic applications — but the precise details of how they interact with DNA need to be ...